Source comparison
CJC-1295 no DAC & Ipamorelin Dosage Guide: Protocol Comparison
The following table outlines the most common research dosing protocols for CJC-1295 no DAC and Ipamorelin, comparing single-peptide and combination approaches across key parameters. CJC-1295 Monotherapy 200-300mcg None 2-3× daily Morning (fasted), post-trainin
This comparison does not assign a generated winner or score.
- The following table outlines the most common research dosing protocols for CJC-1295 no DAC and Ipamorelin, comparing single-peptide and combination approaches across key parameters.
- CJC-1295 Monotherapy
- 200-300mcg
- None
- 2-3× daily
- Morning (fasted), post-training, pre-sleep
- 2-3× baseline
- Effective for GHRH receptor targeting but misses ghrelin pathway synergy. Requires higher absolute peptide quantities.
- Ipamorelin Monotherapy
- Selective GHSR-1a activation without cortisol elevation. Limited by single-pathway stimulation.
- Low-Dose Combination
- 100mcg
- 3-4× baseline
- Cost-effective entry protocol for initial research phases. Allows titration assessment before increasing dose.
- Standard Combination
- 200mcg
- 4-5× baseline
- Most widely researched protocol. Balances synergistic amplification with manageable side effect profile. Optimal for 8-12 week cycles.
- High-Dose Combination
- 300mcg
- 5-7× baseline
- Reserved for advanced protocols after receptor sensitivity assessment. Increased risk of desensitization beyond 12 weeks continuous use.
- Pre-Sleep Only Protocol
- 1× daily
- 30-60 minutes before sleep
- 3-4× baseline (during sleep pulse only)
- Targets the body's largest endogenous GH surge. Reduces daily injection burden but misses morning and post-training amplification windows.